<DOC>
	<DOCNO>NCT02460445</DOCNO>
	<brief_summary>AIMS To study effect decrease iron tissue depot schedule bloodletting insulin sensitivity , carbohydrate metabolism , classic non-classic cardiovascular risk factor patient functional hyperandrogenism ( polycystic ovary syndrome &amp; idiopathic hyperandrogenism ) standard treatment combined oral contraceptive ( COC ) accord usual clinical practice . METHODOLOGY Open label , control , parallel , prospective study 12 month duration , 2 randomize arm follow-up : ) Intervention Group : Patients functional hyperandrogenism standard COC treatment randomly allocate perform schedule phlebotomy third month treatment end study ( 3 time 3-month interval ) . ii ) Control Group : Patients functional hyperandrogenism standard COC treatment randomly allocate follow-up without bloodletting . The whole group patient undergo comprehensive anthropometric hormonal assessment , evaluation classic cardiovascular risk factor ( insulin sensitivity carbohydrate metabolism standard oral glucose test- 75 g ) , lipid profile , ambulatory office blood pressure monitoring , proinflammatory profile , oxidative stress status , autonomic function assessment , iron-related metabolism parameter baseline , 3-month COC treatment reduction iron tissue depot plus OC Intervention Group patient , throughout follow-up treatment COC Control Group patient . If significant relationship circulate hepcidin level elevate ferritin concentration observe , study potential influence mutations/polymorphic variant hepcidin gene ferritin value perform well .</brief_summary>
	<brief_title>Phlebotomy Polycystic Ovary Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Polycystic Ovary Syndrome</mesh_term>
	<mesh_term>Hyperandrogenism</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<mesh_term>Cyproterone</mesh_term>
	<mesh_term>Cyproterone Acetate</mesh_term>
	<mesh_term>Contraceptives , Oral , Combined</mesh_term>
	<criteria>1 . Premenopausal woman functional hyperandrogenism define : Polycystic ovary syndrome ( PCOS ) : Clinical biochemical hyperandrogenism plus ovulatory dysfunction polycystic ovarian morphology . Idiopathic hyperandrogenism : Clinical biochemical hyperandrogenism normal ovulatory cycle normal ovarian morphology . 2 . Combined oral contraceptive pill indication treatment : ) hyperandrogenismrelated dermocosmetic complaint psychoemotional impact ; ii ) endometrial protection ; and/or iii ) contraception desire . 3 . Scheduled phlebotomy acceptation randomly allocate . 4 . Signed informed consent . 1 . Contraindication blood donation . 2 . Plasma ferritin &lt; 76 pmol/l and/or transferrin saturation percent &lt; 15 % . 3 . Anemia ( plasma hemoglobin &lt; 12 g/dl hematocrit &lt; 36 % ) . 4 . Chronic kidney disease ( eGFR &lt; 60 ml/min per 1.73 m2 ) . 5 . Personal history dyslipidemia , hypertension , prediabetes , diabetes mellitus , gestational diabetes cardiovascular event . 6 . Treatment oral contraceptive , antiandrogens , insulin sensitizer , drug might interfere blood pressure regulation , lipid profile carbohydrate metabolism , oral/parenteral iron therapy previous 3 month inclusion . 7 . Previous surgical treatment PCOS . 8 . History blood donation previous 12 month inclusion . 9 . Current history infectious disease , inflammatory disease , liver disease , neurologic disease malignancy . 10 . Eating disorder . Body mass index &lt; 18.5 Kg/m2 . 11 . Hereditary hemochromatosis . 12 . Celiac disease malabsorptive disorder . 13 . Contraindication treatment combine oral contraceptive . 14 . Pregnancy . 15 . Current smoking , recreational drug use excessive alcohol consumption ( &gt; 40 g per day ) .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Functional hyperandrogenism</keyword>
	<keyword>Polycystic ovary syndrome</keyword>
	<keyword>Idiopathic hyperandrogenism</keyword>
	<keyword>Iron tissue depot</keyword>
	<keyword>Phlebotomy</keyword>
	<keyword>Insulin resistance</keyword>
	<keyword>Carbohydrate metabolism</keyword>
	<keyword>Blood pressure</keyword>
	<keyword>Autonomic dysfunction</keyword>
	<keyword>Oxidative stress</keyword>
	<keyword>Blood clotting test</keyword>
	<keyword>Efficacy</keyword>
	<keyword>Side effect</keyword>
	<keyword>Randomized clinical trial</keyword>
</DOC>